Phase I Study of an Autologous Idiotype Vaccine Manufactured by magnICON Technology for the Treatment of Patients With Follicular Lymphoma in First Relapse/Progression
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2014
At a glance
- Drugs Cancer vaccine (Primary) ; Cancer vaccines; Granulocyte-macrophage colony-stimulating factors
- Indications Follicular lymphoma
- Focus Adverse reactions
- Sponsors Bayer Innovation GmbH; Icon Genetics GmbH
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Aug 2013 Planned end date changed from 1 Oct 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 23 May 2013 Planned End Date changed from 1 Jun 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.